ウェビナー

AI is transforming antibody discovery, but better models only come from better data. When you are generating and screening sequences at scale, you need characterization results that are fast, comprehensive, and ready to use without hours of cleanup and reformatting.

The antibody therapeutics sector is rapidly evolving, transitioning from traditional hybridoma methods to single B and AI-driven de novo design approaches, significantly compressing discovery timelines and creating novel binding moieties.

Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured expert presentations from SeromYx Systems and Visterra on two critical areas of antibody and biologic development: Fc-effector function profiling and cell-based neutralizing antibody (NAB) assay design.

This webinar provides an overview of Antibody-Drug Conjugates (ADCs) and expanded drug conjugates (XDCs), with a focus on Biointron's experiences and capabilities.

Watch our webinar on accelerating antibody discoveru. Single B cell sorting-based antibody screening can help identify a population of diverse and functional hits with a shortened timeline. Integrated with our high-throughput expression, validation and developability assay platforms, the path from hits to candidate can be more faster and more efficient with data beyond binding alone.

During the NextGen Biomed 2026 conference in London, Lei Shi, PhD, Senior Vice President of Biointron, discussed Biointron's unique single B cell sorting-based antibody discovery process integrated with our high-throughput expression, validation and developability platforms.

Developability is an increasingly critical concept in antibody discovery and development. Previously associated with late-stage outcomes such as stability and formulation, developability assessment is now integrated earlier in the discovery process to enable multidimensional profiling of lead candidates.

WhenThursday, October 16, 2025 · 11:00 a.m.Eastern Time (US & Canada) (GMT -4:00)Register here >>AboutSuccessful antibody discovery requires more than just access to powerful platforms - it demands the experience to apply them efficiently and strategically.In this webinar, we

Biointron’s Lunch & Learn with KACTUS was held at CIC Cambridge, MA on September 12. The session featured three key speakers: Sagar Kathuria, PhD (Senior Principal Scientist at Sanofi), Alexander Hostetler, PhD (Application Scientist at KACTUS Biosystems), and Gang Liu, PhD (Director of Discovery Services at Biointron). We thoroughly enjoyed hosting the event and the audience’s strong engagement!

Biointron’s Lunch & Learn with MassBio was held in Boston, MA, on May 9. The session focused on the advancements in antibody discovery in the biopharma industry and featured three key speakers: Dr. Hitesh Soni (Director of In Vivo Pharmacology at Tectonic Therapeutic Inc.), Dr. Lei Shi. (SVP at

In this webinar, Dr. Brady Wu will discuss bispecific antibody drugs and their production.

Biointron is thrilled to collaborate with Carterra to bring you an exclusive live webinar: Innovative Methods Advancing Discovery and Characterization of Antibodies

Biointron is excited to announce our upcoming collaborative webinar with the Antibody Society, scheduled for June 26th, 2025. This webinar will feature our speaker, Dr. Gang Liu, Associate Director of Biointron. Dr. Liu will delve into the captivating topic of "AbDrop Speeds: Accelerating Your Antibody Discovery with Single B Solution," providing attendees with a rich and informative exploration of the latest trends and advancements in antibody discovery technologies.

Lei Shi, PhD, Senior Vice President of Biointron, discusses: "Simplified and Humanized: Empowering Human Antibody Discovery with AbDrop™ Solution" during the Antibody Engineering & Therapeutics US 2024 conference in San Diego.